Understanding Large Granular Lymphocytic Leukemia: ICD-10 Codes And Diagnosis
What is Large Granular Lymphocytic Leukemia ICD-10?
Large Granular Lymphocytic Leukemia (LGLL) is a rare type of chronic lymphoproliferative disorder characterized by the presence of abnormally large lymphocytes in the blood and bone marrow. It is classified under the ICD-10 code C94.5.
Code Information
The ICD-10 code for Large Granular Lymphocytic Leukemia is C94.5. This code is used to classify and report cases of LGLL in medical records and billing.
Diagnostic Related Groups (MS-DRG)
Large Granular Lymphocytic Leukemia falls under MS-DRG 820 – Lymphoma and Leukemia with Major O.R. Procedures with MCC (Major Complications and Comorbidities) or CC (Complications and Comorbidities).
Convert to ICD-9 Code
The equivalent ICD-9 code for Large Granular Lymphocytic Leukemia is 289.2.
Code History
The ICD-10 code for LGLL was introduced in 2016 as part of the regular update of the International Classification of Diseases.
Approximate Synonyms
Some approximate synonyms for Large Granular Lymphocytic Leukemia include LGLL, T-cell large granular lymphocytic leukemia, and NK-cell large granular lymphocytic leukemia.
Clinical Information
LGLL is a clonal disorder of the cytotoxic T or natural killer cell lineage. It is characterized by the presence of large granular lymphocytes with a CD3+ CD8+ CD57+ phenotype in the peripheral blood and bone marrow.
Causes
The exact cause of Large Granular Lymphocytic Leukemia is unknown. However, it is believed to be associated with immune dysregulation and genetic mutations.
Symptoms
Patients with LGLL may experience symptoms such as fatigue, weakness, recurrent infections, enlarged spleen, and autoimmune manifestations such as rheumatoid arthritis or neutropenia.
Diagnosis
Diagnosis of Large Granular Lymphocytic Leukemia is confirmed through blood tests, bone marrow biopsy, and flow cytometry to identify the abnormal lymphocytes.
Treatment
Treatment options for LGLL include immunosuppressive therapy with medications such as methotrexate or cyclosporine, as well as biological agents like rituximab. In some cases, chemotherapy or stem cell transplantation may be recommended.
Conclusion
Large Granular Lymphocytic Leukemia is a rare but serious condition that requires careful monitoring and treatment by a hematologist or oncologist. Early diagnosis and appropriate management can help improve outcomes and quality of life for patients with LGLL.
FAQs about Large Granular Lymphocytic Leukemia ICD-10
Q: Is Large Granular Lymphocytic Leukemia a type of cancer?
A: Yes, LGLL is a type of lymphoproliferative disorder that can be classified as a form of leukemia.
Q: What are the risk factors for developing LGLL?
A: The exact risk factors for LGLL are not well understood, but it is believed to be associated with immune dysregulation and genetic mutations.
Q: What are the treatment options for Large Granular Lymphocytic Leukemia?
A: Treatment options for LGLL may include immunosuppressive therapy, biological agents, chemotherapy, or stem cell transplantation.
Q: Can Large Granular Lymphocytic Leukemia be cured?
A: While there is no cure for LGLL, treatment can help manage symptoms and slow the progression of the disease.
Q: How common is Large Granular Lymphocytic Leukemia?
A: LGLL is considered a rare condition, accounting for only a small percentage of all leukemia cases.
